Aims: To determine the relative utility of in-situ testing for hepatitis E virus (HEV) RNA and paraffin-section polymerase chain reaction (PCR) to diagnose HEV infection in paraffin-embedded clinical liver biopsies, and to correlate with clinicopathological characteristics.
Detection of viral hepatitis E in clinical liver biopsies
Aims: To determine the relative utility of in-situ testing for hepatitis E virus (HEV) RNA and paraffin-section polymerase chain reaction (PCR) to diagnose HEV infection in paraffin-embedded clinical liver biopsies, and to correlate with clinicopathological characteristics.
Methods and results:
We evaluated in-situ and quantitative PCR (qPCR)-based approaches to identifying HEV in clinical liver biopsies from infected patients from multiple centres, correlating with clinical setting (immunocompetent, allograft or immunosuppressed native liver) and histological findings. Thirty-six biopsies from 29 patients had histological data, 27 and 23 of which had satisfactory material for in-situ RNA testing and tissue qPCR, respectively. Both approaches specifically identified HEV infection, but tissue qPCR was significantly more sensitive than RNAscope in-situ testing (P = 0.035). In immunocompetent but not immunosuppressed patients the tissue qPCR yield correlated with the severity of lobular hepatitis (rho = 0.94, P < 0.001). qPCR viral yield was comparably high in allografts and immunosuppressed native livers and significantly greater than with native liver infection. Immunosuppressed patients showed reduced severity of hepatitis and cholestatic changes, compared with immunocompetent patients. Indeed, HEV-infected liver allografts could show minimal hepatitis for many months. In individual cases each technique was useful when serum was not available to identify chronic infection retrospectively (in biopsies taken 4-31 months before diagnosis), to identify persistent/residual infection when
Introduction
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide, and our understanding of the impact of HEV infection in developed countries has changed. Previously considered a traveller's disease acquired in endemic regions via contaminated water, locally acquired infection is now understood to be prevalent. HEV genotypes 1 and 2 are endemic in some developing regions, while genotypes 3 and 4 are established in zoonotic reservoirs from which sporadic or small cluster outbreaks of locally acquired infection originate. The predominant manifestation is self-limited subclinical or mild acute hepatitis that mimics drug-induced liver injury in 3-13% cases. 1, 2 Risk factors for severe hepatitis include pregnancy (genotype 1) or pre-existing chronic liver disease. 3, 4 At least 5% patients present instead with neurological symptoms; 5, 6 other presentations include polyarthralgia and rash 7 or acute pancreatitis. 8 HEV infection can become chronic in immunosuppressed patients, including recipients of cancer chemotherapy or solid organ allografts. 9 Mixed HEV strain or genotype acute infections have been described. 10, 11 Pathological studies in HEV-infected primates show a change from initial cytopathic liver injury (hepatocyte swelling, minor inflammation) to reactive hepatitis and transaminitis, which coincide with the appearance of antiviral IgM and concomitant dwindling of serum viral RNA. 12, 13 In humans, the pathology of severe acute hepatitis E in endemic regions is described for epidemic outbreaks in Delhi 1955 14 and Kashmir 1978, 15 while Morrow recorded the microscopic features from 158 liver biopsies of endemic sporadic acute hepatitis in Ghana. 16 Two broad histological patterns were described: first, a classic non-specific acute hepatitis, including hepatocyte ballooning, portal inflammation, hepatocyte binucleation, Kupffer cell hyperplasia, hepatocellular and canalicular bile with highly variable degrees of necrosis; secondly, a more cholestatic acute hepatitis with dominant canalicular bile, pseudoglands and variable, sometimes rare, acidophil bodies. 15 , 16 Agrawal made similar observations among 11 cases of fatal acute hepatitis E infection, also finding occasional lymphocytic cholangitis and noting that pseudoglands were more extensive among patients with higher bilirubin. 17 Morrow observed that the pathological pattern tended to remain consistent across serial liver biopsies. 16 Reports on the pathology of locally acquired hepatitis E naturally represent a severe subset, either because of pre-existing chronic liver disease that is reflected in the biopsy 4, 18 or intrinsically severe viral hepatitis. Again, cases fit a pattern of classic acute hepatitis 19 or cholestatic hepatitis, 19-21 the latter with notable neutrophil cholangiolitis and portal neutrophils. Lymphocytic cholangitis is described, 19, 21 occasionally severe. 22 Some cases show minimal or no hepatitis, with only sinusoidal lymphocytosis 18 or canalicular cholestasis in chronic liver disease as clues to a second injury. 23 Pathological descriptions in immunosuppressed patients are less comprehensive. Most cases are genotype 3, although there are case reports of allograft infection with genotype 4 causing fulminant cholestatic hepatitis or accelerated cirrhosis. 24, 25 One report describes genotype 7 (camel) HEV infection of a liver allograft. 26 Early findings in liver allografts with accelerated fibrosis linked to chronic HEV infection included hepatocyte single cell death with no or minimal lymphocytic lobulitis, no ballooning or cholestatic features and mild portal lymphocytic infiltration. [27] [28] [29] [30] This evolved in some to mild-moderate lymphocytic portal, interface and lobular hepatitis with fibrosis, still without notable cholestatic features or ballooning. [28] [29] [30] [31] [32] [33] [34] Pathological descriptions in other solid organ allograft recipients are similar, 35, 36 sometimes with portal lymphoid aggregates and bile duct inflammation. 37 There are few pathological descriptions in other immunosuppressed patients. 38, 39 Taken together, HEV infection of immunosuppressed patients can manifest only subtle or non-specific pathological changes initially, which with mild changes to transaminases makes early clinical recognition a challenge.
We aimed to determine whether in-situ testing for HEV RNA in routine liver biopsies was feasible and of comparable sensitivity to paraffin section PCR, to establish the relative utility of these approaches. Secondarily, we aimed to characterize examples of acute and chronic HEV, correlating the RNA findings with clinicopathological characteristics. Molecular virological screens have not identified a viral virulence determinant for HEV, concluding that host factors are more relevant to clinical severity, [40] [41] [42] so it seemed reasonable to group the cases by clinical setting.
Materials and methods
The study group comprised 36 paraffin-embedded indication liver biopsies (including one hepatectomy) from 29 HEV-infected patients. Clinical controls included indication biopsies of native liver from four uninfected (anti-HEV IgM and IgG-seronegative) patients. The study biopsies were collected from seven centres within the United Kingdom, Holland and France; the diagnosis was established locally on the basis of seropositivity for anti-HEV IgM and/or viraemia with serum PCR. We also included all prediagnosis allograft biopsies from one centre (Edinburgh). Biopsies were formalin-fixed, except one centre that used Duboscq-Brasil fluid. Standard histological stains were reviewed by a pathologist (C.O.C.B.) and scored semiquantitatively (zero, minimal, mild, moderate, severe) for conventional metrics including portal, interface and lobular hepatitis, individual hepatocyte dropout (apoptosis/necrosis), specific infiltrating cell types (plasma cell, eosinophil, neutrophil), sinusoidal mononucleosis, ductular reaction, bile duct inflammation and atrophy (see Supporting information, for scoring details). The presence of confluent necrosis, large droplet steatosis (%), steatohepatitis, iron overload, cholate stasis, canalicular and ductular cholestasis were also recorded. Fibrosis was scored 0-6 as described by Ishak et al. 43 . The histological features of two patient biopsies have been described previously by us. 23 The study has local ethics approval (REC07/S1102/21).
I N -S I T U H Y B R I D I Z A T I O N
This was performed on 4-lm tissue sections using the RNAscope kit 2.0 HD (Advanced Cell Diagnostics, Hayward, CA, USA) with the recommended standard hybridization protocol on an automated stainer (Leica BondRX). Pooled oligonucleotide probes specific for hepatitis E genotypes 1-4 were used (Supporting information, Data S1).
Consecutive sections were stained for HEV, positive control [the housekeeping PPIB gene product peptidylproyl isomerase B (cyclophilin B)] and negative control [bacterial dapB (dihydrodipicolinate reductase) gene product]. A positive RNA signal manifested as crisp homogeneous dark-brown dots, lacking the golden refractile quality or irregularity of iron or lipofuscin granules when those were present, or zonal distribution. RNA dots in positive cases and controls were mainly cytoplasmic, although could also overlie nucleus in cells with numerous cytoplasmic dots (probably representing cytoplasm overlying nucleus or some target RNA within the nucleus). Scoring was performed by two observers independently at a double-headed microscope on the same five microscopic fields, viewed at 9400 magnification. For PPIB control evaluations, the average number of cytoplasmic RNA dots per hepatocyte was categorized 0-5 (negative, sporadic single dot, 1-4 dots, 5-9 dots, 10-14 dots, 15 + ). Cases averaging fewer than five cytoplasmic PPIB dots per hepatocyte were excluded from further analysis. 44 For HEV and dapB, the number of hepatocytes per field with cytoplasmic RNA dots was recorded (specifying single/multiple dots per scored cell). Hepatocyte dapB cytoplasmic staining amounted to rare cells with single dots (average 0.25 cells per 9400 field), confirming low background. Purely nuclear staining in a hepatocyte was also rare and similar in prevalence between test sections and negative controls ( Figure S1 ); this was usually a single nuclear dot, likely to reflect sporadic non-specific nuclear hybridization, which increases with tissue overdigestion.
Q U A N T I T A T I V E R E A L -T I M E T I S S U E P C R ( Q P C R ) F O R H E V R N A
Three to five 10-lm-thick serial sections were cut from each block for PCR analysis. RNA was extracted using the RNeasy FFPE kit (Qiagen, Crawley, UK) then qPCR was performed on 250 ng RNA with the ceeram TOOLS â hepatitis E virus detection kit (bioMerieux, Basingstoke, UK), whose detection limit was considered to be 0.2 IU/250 ng RNA. Positive HEV samples were confirmed with replicates and quantified using the WHO nucleic acid standard for HEV (Paul Erlich Institute, Langen, Germany). The integrity of RNA samples was assayed using the 18srRNA control kit (Eurogentec, Southampton, UK).
S T A T I S T I C S
Data were analysed and charted according to data type using Minitab 17 statistical software as indicated in the text. Contingency table comparisons between categorical variables were evaluated with Fisher's exact test. Correlations with ordered categorical data used Spearman's rank-order correlation. Comparisons of means were made by analysis of variance (ANOVA) with simultaneous 95% confidence limits, using Dunnett's method for multiple comparisons with a control, or Tukey's method for pairwise comparisons of means between groups. Joint 95% confidence limits (CL) or P < 0.05 were used to indicate significance.
Results

P A T I E N T S A N D S A M P L E S
The HEV-infected cases included 23 native liver biopsies from 22 patients (eight chronic infection) and 13 allograft liver biopsies from seven patients with chronic infection (Table 1) . Histological metrics were scored for all 36 biopsies. All 23 samples with tissue qPCR data had in-situ RNA evaluation. HEV genotyping from serum (eight patients) or biopsy (seven patients, Supporting information, Data S1) showed genotype 3c or 3f in 14 patients (five immunocompetent, eight native immunosuppressed, one allograft) and genotype 1 in one immunocompetent patient (case 2, travel-acquired in India).
Twelve immunocompetent patients had an indication liver biopsy related to severe acute HEV hepatitis. All seven patients with serum PCR testing at presentation were viraemic (1-16 and 25 days prebiopsy). Three patients had significant liver fibrosis (Ishak stage > 2), attributed to alcohol, metabolic syndrome and autoimmune hepatitis, respectively.
Ten heavily immunosuppressed patients had native liver biopsies (four renal transplants, one heart transplant, five haematological malignancy -two with stem cell transplants). Eight were chronically viraemic at biopsy (cases 4, 15, 16, 17, 22, 23, 25, 33) , two with mild fibrosis (Ishak stages 1-2). The other two patients (cases 5 and 7) had acute hepatitis, with viraemia and IgM sero-positivity 11 days prebiopsy. Case 5 became serum PCR-negative 8 days before biopsy, suggesting cleared infection, in a background of alcohol-attributed steatohepatitis with moderate fibrosis. Case 7 became IgG-seropositive at next testing several months later.
Nine allograft biopsies from five patients preceded the diagnosis of HEV infection (by median 419 days, range: 103-923). However, stored contemporary serum available for four biopsies from three patients showed that viraemia was already present for each.
I N -S I T U R N A S C O R I N G A N D T I S S U E Q P C R T E S T I N G F O R H E V
All formalin-fixed biopsies with tissue available for insitu testing had a satisfactory RNA control signal. However, Duboscq-Brasil-fixed biopsies gave no control signal despite testing different conditions, so were excluded, leaving 27 informative biopsies from 22 patients. There was no other evidence of a centre effect on RNA quality (PPIB grade). There was also no correlation between an incrementally higher PPIB score and tissue qPCR yield for HEV (Spearman's rho 0.047), suggesting that the PPIB grade cut-off ensured adequate RNA quality to detect HEV (Figure 1A) .
In-situ staining for HEV manifested in hepatocytes as discrete brown cytoplasmic dots ( Figure 1B,C) . Infected hepatocytes tended to be placed randomly within lobules when few were apparent, with variably sized loose clusters in cases with more prevalent positive-staining cells. Positive-stained hepatocytes were sometimes more numerous towards the periphery of the biopsy core, suggesting fixation-related effects on sensitivity. There was no consistent topographic relationship of positive-stained hepatocytes with lobular inflammation, although such areas could be identified ( Figure 1D ). Positive-stained hepatocytes with cytoplasmic dots also showed some dots overlying the nucleus, but isolated nuclear staining of hepatocytes was rare, matching negative controls ( Figure S1 ). However, mononuclear inflammatory cells and biliary epithelium showed occasional nonspecific isolated nuclear hybridization signals that were also apparent in negative controls (dapB). With this confounder, we did not identify convincing biliary epithelial cytoplasmic staining for HEV; the use of more aggressive digestion was unhelpful to increase sensitivity due to increased confounding non-specific nuclear hybridization signals within portal cells.
As the two observers differed in counts of HEV-positive hepatocytes per field by an average of only 0.88 cells/field (95% CL: 0.096, 1.665), we represented each case by the median of the combined 10 field counts of the two observers, and separately by whether both observers agreed that at least one hepatocyte contained multiple cytoplasmic RNA dots. Alternative metrics (e.g. maximum field count) were correlated positively but did not add extra discriminatory information (data not shown). Figure 2A shows a box-plot of in-situ HEV + hepatocyte counts per biopsy according to the clinical group. The mean count per clinical group was significantly greater than uninfected controls (P = 0.001, ANOVA with Dunnett multiple comparisons). Allografts had a higher mean than other groups (P = 0.001), because individual biopsies scored highly more consistently. Uninfected controls had consistently low counts (median 0.5, range for individual fields 0-6, always a single RNA dot per hepatocyte). Therefore, we adopted a threshold of 6 (reference line on Figure 2A ) above which a median count across all scored fields was taken to suggest HEV infection, to confidently ensure specificity of 100%. In this way, 13 of 27 (48%) study biopsies were designated HEVpositive. The positive-scoring biopsies were most often allografts (eight of nine biopsies, P = 0.02), compared with immunosuppressed native (two of six) or immunocompetent patient biopsies (three of 12). The highest-scoring cases were distributed among all three groups and included the genotype 1 infection (case 2). If, alternatively, we selected as positive those cases where both observers agreed that there was at least one hepatocyte with multiple cytoplasmic RNA dots, then all control cases were negative and 13 cases (48%) were again positive, including nine also selected using the median count threshold above (Figure 2A) . Therefore, we combined the two approaches, such that cases with inadequate median count were designated positive if agreed to have at least one hepatocyte with multiple dots. This improved sensitivity to 17 of 27 cases (63%) positive without compromising specificity. Comparison of the in-situ HEV scoring with the tissue qPCR was possible for 23 study biopsies from 19 patients ( Figure 2B ). As expected, HEV was detected in the study groups but not uninfected controls (100% specificity). The high qPCR HEV yields from allografts and immunosuppressed native livers were significantly greater than from immunocompetent patients, but not significantly different from each other (Tukey simultaneous 95% CL).
C O R R E L A T I O N O F I N -S I T U H E V S C O R E S W I T H C L I N I C A L S T A T U S A N D T I S S U E Q P C R
Tissue qPCR was more sensitive than in-situ counting to detect HEV [21 of 23 (91%) versus 14 of 23 (61%) with combined median/multidot count (P = 0.035, Fisher's exact test), or 11 of 23 (48%) biopsies with either median or multidot count alone (P = 0.0031)]. The reduced sensitivity of in-situ counting was clear for immunocompetent patients (two of 10 versus eight of 10, P = 0.023, Fisher's exact test) but not for allografts (seven of eight versus eight of eight, P = 1); immunosuppressed native liver numbers were too small for a confident conclusion (two of five versus five of five, P = 0.16).
Reviewing the two qPCR-negative biopsies, one (case 21) was acute hepatitis biopsied 25 days after diagnosis with viraemia, and probably reflected clearance of infection. The other (case 24) was severe acute hepatitis in which the biopsy showed collapse and ductular reaction with only rare surviving hepatocytes, so may have reflected a sampling deficit for hepatocytes or immune clearance. The hepatectomy with a very low HEV yield (sample 6b) also had multiple hepatocyte RNA dots in some cells on in-situ testing but a low median count. This patient had cleared viraemia on serum retesting 1 month after diagnosis and biopsy (sample 6a), so the low yield might reflect almost cleared infection. By contrast, another patient (case 5) showed HEV with both in-situ and qPCR analysis, despite having cleared viraemia on serum testing 6 days earlier. This patient had chronic leukaemia, so was immunosuppressed significantly and still harbouring HEV within the liver, although not viraemic on point testing of serum.
All seven allograft biopsies (four patients) taken before diagnosis of HEV infection were HEV-positive with at least one tissue test, including all six tested with qPCR (Figure 2A,B) . The biopsy without material for qPCR (27a) had a positive in-situ score similar to the subsequent qPCR-positive biopsy (27b). The biopsy scoring negative with in-situ testing (8a) had similarly high qPCR yields to the other cases, including a follow-up biopsy (8b) with a positive in-situ count. Thus, tissue RNA analysis showed that all four of these patients carried chronic HEV infection many months (4, 14, 14, 31 months) before diagnosis.
These findings were corroborated with retrospective serum testing in the two patients with stored serum.
C O R R E L A T I O N W I T H H I S T O L O G I C A L A N A L Y S I S
While not a cohort, the different clinical settings merit description of the range of histological appearances (see also Figures S2-S4) . Immunocompetent patients biopsied during acute HEV infection typically showed moderate/severe interface and lobular lymphocytic hepatitis with some admixed portal and lobular plasma cells (Figure S2 ), often with mild biliary features, including ductular reaction and duct epithelial reactivity, but no more than minimal duct inflammation or portal oedema and without periduct oedema. Canalicular cholestasis was common (nine of 13 biopsies; moderate/severe in six), including all four patients with significant chronic liver disease (Ishak fibrosis > 2). Indeed, cholestasis was the only prominent manifestation in one patient with preexisting chronic steatohepatitis. The biopsies after recently cleared infection (21) and almost cleared infection (6b) also showed canalicular cholestasis [not present in an earlier biopsy (6a), with hepatocyte dropout and portal, but not lobular, hepatitis. The immunocompetent patient biopsies had a strong positive correlation between lobular hepatitis severity and the tissue qPCR yield for HEV (Spearman's rho 0.936, P < 0.001). This correlation was absent for immunosuppressed patients, whose biopsies almost all had high HEV qPCR yields ( Figure 2B ). Contemporary serum alanine aminotransaminase (ALT) values in immunocompetent (but not transplanted) patients also correlated significantly with lobular hepatitis severity (Spearman's rho 0.771, P = 0.015) and had a marginally significant correlation with the in-situ HEV count (Spearman's rho 0.643, P = 0.08); however, correlation with tissue qPCR yield was not significant (Pearson's correlation coefficient 0.51, P = 0.29).
Lobular hepatitis was usually more severe in immunocompetent patients compared with others (moderate-severe in eight of 13 (62%) versus four of 23 (17%), P = 0.011, Fisher's exact test). Canalicular cholestasis was also common in HEV-infected immunocompetent patients, but was not a feature of allograft HEV infection (nine of 13 versus none of 13; P = 0.013, Fisher's exact test) (Table 2, Figure 3) . While allografts at diagnosis of HEV infection usually showed prominent portal hepatitis (moderate or severe in three of four), allografts biopsied before HEV was diagnosed usually showed minimal or mild portal hepatitis, no or minimal interface and lobular hepatitis, only minimal hepatocyte dropout, no prominence of plasma cells or cholestatic features and usually minimal or mild sinusoidal mononuclear cell infiltration ( Figure 3, Table 2 , Figure S4 ).
Lobular plasma cells were associated with moderate-severe lobular hepatitis in acute HEV infection (eight of 10 biopsies), and perhaps as a result were apparent in native more often than allograft biopsies (nine of 23 versus one of 3, P = 0.059 Fisher's exact test). Portal bile duct changes (epithelial reactivity, inflammation) and other infiltrating cell types (eosinophils, neutrophils) showed no particular correlation.
Discussion
The present results show that in-situ RNA staining is less sensitive than qPCR to detect HEV in routine clinical liver biopsies. Nevertheless, in-situ staining specifically identified HEV, as determined by comparisons against the tissue qPCR, contemporary serum PCR and uninfected control biopsies. In-situ testing can identify virus when retrospective serum testing is not possible (as for two liver transplant patients in this study), or if there is insufficient tissue for PCR (as with one prediagnosis allograft biopsy). This has particular value in allografts to establish the time-lines of chronic infection for research or clinical purposes.
The occurrence of HEV RNA-staining in hepatocyte cytoplasm, either in scattered single cells or sometimes in loose clusters, but otherwise without a particular pattern, agrees with observations in experimentally infected primates 45, 46 and clinical biopsies [47] [48] [49] using immunolabelling or older in-situ RNA detection methods. While those and the present study did not identify convincing non-hepatocellular HEV staining, the virus is excreted in bile and some animal studies have suggested viral replication in biliary epithelium, 45 while virus-like particles have been described in ductular-lining cells in one patient. 50 It is not clear why the in-situ counts did not correlate better with the tissue qPCR yield for virus, even allowing that the PCR sample was several-fold larger than a 4 lm tissue section. Stronger digestion protocols did not increase in-situ scores. The RNAscope probe-set was designed to detect HEV genotypes 1-4, and identified both genotypes 1 and 3; moreover, successive allograft biopsies from one patient (8a, 8b) had similar high qPCR yields, yet only one scored positive with in-situ median counting, suggesting that the issue is not wholly with genotype or subtype detection. We cannot exclude that some variable aspect of fixation (delay, duration) is prejudicing viral RNA detection by the in-situ probe, even though the positive control PPIB probe counts and the qPCR method did not seem affected. Nevertheless, routine formalin-fixed paraffin-embedded clinical samples from different centres provided positive staining, suggesting that such samples are usually adequate for in-situ detection although, importantly, other fixatives such as Duboscq-Brasil fluid can be unsuitable for both PCR and in-situ evaluation.
In addition to the present data, PCR of archival liver biopsies has been shown recently to identify unrecognized HEV infection of small numbers of patients categorized previously as hepatitis of unknown origin, 19 drug-induced liver injury 51 and among archival liver transplant biopsies. 30 Taking all factors into account, tissue PCR testing is robust, more sensitive, easier and cheaper than in-situ RNA testing when sufficient tissue is available. The present correlation of tissue viral load (qPCR) with the degree of lobular hepatitis in immunocompetent patients, and in turn the correlation of lobular hepatitis with serum ALT, was perhaps intuitive, but affirms that histological activity reflects the underlying disease biology and immune response directly. 12 The data also highlight how this correlation is unlocked with immunosuppression, where tissue viral loads were extreme and hepatitis subdued. Clearance of viraemia did not necessarily imply clearance of infection: the present identification of viral RNA in the liver by both tests in one immunosuppressed patient when contemporary point testing of serum was negative re-emphasizes the need for follow-up testing where the clinical setting suggests a potential for prolonged infection, particularly as serological testing is insensitive in such patients. Protzer also noted two aviraemic liver allograft patients with contemporary HEV-RNA-positive liver biopsies, although both appeared to eventually clear the infection biochemically. 30 In typical self-limited infection of immunocompetent patients, HEV is detectable in stool for 2-4 weeks after viraemia subsides, 52 presumably reflecting dwindling hepatic viral release into bile, in which the temporary discrepancy with serum testing does not usually have a longer-term significance. However, HEV recurrence after apparent clearance and seroconversion is also documented months after leukaemia chemotherapy (genotype 4) 53 or stem cell transplantation (genotype 3), 54 and we have encountered a similar case. Such examples indicate that aviraemic low-level hepatic persistence of HEV is possible in certain clinical settings linked to immunosuppression; while extrahepatic reservoirs are possible, liver is the intuitive harbour, as observed in this study.
The present histological findings differed between clinical groups of HEV infection, although all but one patient genotyped had type 3 infection. First, a cholestatic pattern of hepatitis was relatively common in severe acute hepatitis E subject to biopsy, as reported previously. [15] [16] [17] [19] [20] [21] In three different patients cholestasis was also, respectively, the dominant manifestation (in prior chronic liver disease) or developed during HEV clearance, or persisted shortly after viral clearance. Pre-existing chronic liver disease was also common, in agreement with indication biopsy-based series of locally acquired acute infection. 4, 18 Cholestatic features were less common in immunosuppressed patients, agreeing with the lack of mention of this feature in previous descriptions, and presumably reflecting the muted inflammatory disruption of liver cyto-architecture and function, together with an acquisition bias compared with immunocompetent patients, in whom such biochemically mild disease would not trigger a biopsy. Indeed, the histological findings attributable to HEV in liver allografts with persistent infection could be minimal for many months, as also found recently by Protzer and colleagues among their four cases. 30 In such a setting, where the histology is not specific and potentially falsely reassuring for 'significant' hepatitis, it may be for the pathologist to articulate the need to exclude HEV infection with specific serum PCR testing. The present allograft cases were biased towards early infection by the inclusion of pre-diagnosis biopsies. However, progressive fibrosis is well documented with chronic HEV infection of liver allografts and in other severely immunosuppressed patients. 24, 28, [32] [33] [34] 37, 39 In conclusion, testing of clinical biopsy material can identify HEV infection directly. This is useful for archival material when stored serum is unavailable, including for research purposes, retrospective diagnosis, determining chronic infection timelines and potentially to identify persistent low-level infection more sensitively under immunosuppression. Tissue qPCR can provide rapid in-house diagnosis of HEV infection in difficult cases on current or past biopsies where pathological or clinical suspicion is aroused.
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